about
ENDOCRINE TUMOURS: Imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approachClinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma.MCM5 as a target of BET inhibitors in thyroid cancer cellsClinical implications of BRAF mutation in thyroid carcinoma.Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer.Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.XL184 (cabozantinib) for medullary thyroid carcinoma.Targeting histone deacetylase in thyroid cancer.Differentiated thyroid carcinoma: defining new paradigms for postoperative management.Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature.BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study.Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology.Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers.PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case reportOverexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules.Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer.Cyclic AMP-response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells.Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.RET mutation and increased angiogenesis in medullary thyroid carcinomas.Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer.Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells.Temporal Changes in Thyroid Nodule Volume: Lack of Effect on Paranodular Thyroid Tissue Volume.PFAPA syndrome in a young adult with a history of tonsillectomy.A NOVEL DOUBLE MUTATION VAL648ILE AND VAL804LEU OF RET PROTO-ONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2.Somatic amplifications and deletions in genome of papillary thyroid carcinomas.The natural history of benign thyroid nodules.Unmasking aortic dissection in patients of transient global amnesia: case report and diagnostic algorithm for the emergency department.Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy.Expression and localization of the sodium/iodide symporter (NIS) in testicular cells.Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients.Interobserver agreement of various thyroid imaging reporting and data systems.Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory.
P50
Q28072249-3845F74E-87A3-4A2E-8DDD-00615777A010Q33842355-31AD8504-26EC-44B3-BAF3-3055829B494DQ33995708-D9B28BDE-262E-4BE9-A920-11356FC8AB36Q36036551-E2E1C44D-EE2C-4084-A0D3-36771665F007Q36965945-236D3D38-E14E-4372-B90C-09100776A12BQ37109044-EB57E419-6D46-45AA-BBA9-998804A7BC67Q37110973-8C472239-8973-4044-A02B-19A3A0FAD595Q37349800-E9EE6BD1-3412-4734-B1E2-9CF2304FD5E7Q37840101-F547B292-57EA-4EB7-A464-CFEBEA24F6D0Q38066990-90EB1BDB-8800-4194-9F71-FE9990F3CB2DQ38097718-10129DB2-5511-49AF-B54D-48BB3B85F179Q38098931-09965DEA-68DF-4B96-AE7B-DB79FB6C13F4Q38270665-986052CE-ED85-47AC-8C92-C5733CFBBE8AQ38354692-2762E3A1-3E17-48D7-8162-B58300BE5AE3Q38566267-605321AC-74D3-41CA-B980-DE1479726B47Q38571991-C82D90E3-6A0C-4EDC-B6CB-3EA92B5CEAB4Q38835322-7333CB31-87A9-47F2-A1F9-1F8FE836E0EDQ38891514-BC362D03-B9C0-4E01-9836-AFFB8EC7BB97Q38971872-92C246B5-0E0F-4B4A-BBCF-CE809C426F3FQ39020838-B099E2DA-3541-4B73-9B6D-906D5F9223B7Q39041934-A7B479C4-3664-4619-9235-1D20704D4588Q39225326-A8891C7C-1B4B-4923-A27B-E18BEFC7CD0EQ39349197-F26646FF-6AEF-46F9-AB3C-1CADE8D48362Q39363384-372D35E4-E2BB-494A-AF77-CB20B2F632BBQ39424030-B2047005-F762-4041-9B18-35457BCE68BEQ39611692-CDD09874-8CD2-47E2-9F3F-5A0E6ABB2ADDQ39760743-C742602C-56CE-48F3-8D1E-0AA63008D93DQ39771358-07419693-D9A3-4333-A6BF-AEE0071ABA0AQ40083652-5FD9BDBC-03F1-4FFD-946D-DBC77B53F720Q40334945-3DED7909-6A62-4786-9AE7-F843EC6D9528Q40655217-31E79F4C-55F6-43AD-B1BD-1AB9644136FFQ41088523-8B435BD3-D31B-403C-9AFD-28827F6B3DFEQ41312346-38BB45A6-D427-4CDD-8092-CBC0884EC3C2Q41984200-6852600A-1B85-4444-8294-3ADAF934228EQ42486234-55B958C4-8608-4A0B-8820-6A0017736858Q44823249-1D6F1B25-0DC5-4143-8AE6-2929D0CB1B53Q46342275-89F28A59-9C1D-45E5-9A4A-1E661FFE4B60Q46855472-B6F8F87F-F355-4CC8-9A9E-5625B8834CE8Q47153152-5531D9D8-13CD-47EB-BE6F-62DA85712C0BQ47819111-078D521C-4B9A-4560-9198-FA4231A1D6EF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Cosimo Durante
@ast
Cosimo Durante
@en
Cosimo Durante
@es
Cosimo Durante
@nl
type
label
Cosimo Durante
@ast
Cosimo Durante
@en
Cosimo Durante
@es
Cosimo Durante
@nl
prefLabel
Cosimo Durante
@ast
Cosimo Durante
@en
Cosimo Durante
@es
Cosimo Durante
@nl
P106
P1153
57191540537
6603928816
P31
P496
0000-0002-1791-5915